Dr. Judith Richter - Founder and Chief Executive Officer

Dr. Judith Richter is an accomplished entrepreneur and among the most distinguished business leaders within the Israeli industry. Dr. Richter, who co-founded Medinol in 1993, has been its Chief Executive Officer ever since.

Under her leadership, Medinol fundamentally transformed the interventional cardiology industry through innovation and revolutionary technology. With an extremely cost efficient manufacturing operation and best-in-class products, Dr. Richter grew Medinol to become a significant player in the stenting industry internationally, highly reputable for its commitment to promote scientific advances and health.

Concurrent with Medinol, Dr. Richter is the founder and an active board member of several other private medical device companies – all focusing on the development of novel devices and breakthrough innovations in the medical field. In addition, Dr. Richter serves as a board member of Mobileye NV, listed on NYSE.

Previously, Dr. Richter founded and served as the CEO of Medcon Ltd., a global provider of web-based cardiac imaging and information management. Dr. Richter successfully led the business until it was acquired by McKesson in 2005.

Among other business engagements, Dr. Richter served on the board of several Israeli corporations, including Bezeq Ltd. Dr. Richter also held a senior position at Teva Pharmaceutical Industries Ltd., one of the largest pharmaceutical companies in the world.

Dr. Richter’s extensive experience in the industry was preceded by a career in the academia. Dr. Richter was a faculty member for over 10 years at Tel-Aviv University’s Graduate School of Business, where she specialized in corporate strategy and decision making under uncertainty.

Today, Dr. Richter serves as a member of the Executive Committee of The Hebrew University of Jerusalem.

Dr. Richter is the recipient of the Ramniceanu Prize in Economics for 2013 awarded by Tel-Aviv University in recognition for her exceptional contribution to Israel's economic, industrial and technological development. She is also an Honorary Fellow of The Hebrew University of Jerusalem since 2013. 

Dr. Richter is a graduate of The Hebrew University of Jerusalem, and holds a Ph.D. in Organizational Psychology from Boston University.

Dr. Kobi Richter - Founder, Chairman and Chief Technology Officer

Dr. Jacob (Kobi) Richter, who co-founded Medinol, is the company's Chief Technology Officer and leads Medinol’s research & development, manufacturing, quality and regulatory affairs.

Under his leadership, Medinol fundamentally transformed the interventional cardiology industry through innovation and revolutionary technology. With an extremely cost efficient manufacturing operation and best-in-class products, Dr. Richter grew Medinol to become a significant international player in the stenting industry, highly reputable for its commitment to promote scientific advances and health.

Prior to founding Medinol in 1993, Dr. Richter co-founded Orbotech, a leading microelectronic product company listed on NASDAQ. He was the company's head of product development and later director of marketing and product development. Currently Dr. Richter is a member of Orbotech's board of directors.

Dr. Richter has also worked as a post-doctoral and research fellow at the Artificial Intelligence Laboratory and Brain Research Department of the Massachusetts Institute of Technology (MIT), and served as head of research and development for the Israeli Air Force.

Dr. Richter has a Ph.D. in Physiology and Pharmacology from Tel Aviv University. He currently serves on the Cardiac Council of Columbia University Medical Center, and on the Advisory Board of the Center for Brains, Minds and Machines (CBMM) in the McGovern Institute for Brain Research, at the Massachusetts Institute of Technology’s Department of Brain and Cognitive Sciences.

Dr. Yoram Richter - Chief Scientific Officer

Dr. Yoram Richter has been with Medinol since 1994, and serves as its Chief Scientific Officer, he is responsible for future research and development projects. In addition to his role at Medinol, Dr. Richter is Vice President for Research and Development at BIOrest, a company developing a targeted systemic anti-inflammatory drug for cardiovascular and other indications. He is also Chief Scientific Officer of Microtech – a company developing sub millimeter implantable sensors – and Chief Scientific Officer of Valve Medical – a company developing a unique percutaneous aortic valve.

Dr. Richter holds a B.Sc. in Physics and Computer Sciences from Tel Aviv University, an M.Sc. in Electrical Engineering from the Massachusetts Institute of Technology, and a Ph.D. in Medical Engineering from Massachusetts Institute of Technology. His Ph.D. thesis concentrated on the physical and biological processes leading to atherosclerosis and published important papers and editorials on the subject of bifurcation treatment.

Dr. Eran Kaplan - VP R&D and Technologies

Dr. Kaplan is with Medinol since 2007. His responsibilities include all aspects of research, product development, manufacturing technologies and core technologies.

Previously Dr. Kaplan was the General Manager of the North America Operations of Bioview Inc. Prior to this position, he led the development of advanced diagnostic systems for the early detection of cancer relapse, at Bioview. Earlier in his career, Dr. Kaplan was a Project Manager in Applied Materials Israel, and a Systems Engineer and Physics Group Leader at Neuromedical Systems Israel.

Dr. Kaplan holds a B.Sc. in Physics, cum laude, from Tel Aviv University, and earned his M.Sc. and Ph.D. in Physics from the Weizmann Institute of Science, Israel. His Ph.D. thesis won the H. Landau award for the most outstanding thesis in 1994.  

Michal Hershkovitz - VP Clinical & Regulatory Affairs

Michal Hershkovitz joined the company in 2008 and she is responsible for the clinical and regulatory activities of Medinol.

Prior to joining Medinol, Ms. Hershkovitz worked for Teva Pharmaceutical Industries, where she led global teams in the regulatory field, medical assessment and  knowledge management.

Ms. Hershkovitz holds a B.Sc. in Chem.Eng., she is also a graduate of a Regulatory Affairs Special Program at the University of Wales and holds MBA diploma from the University of Haifa.

Dr. Daniel Levy - VP Quality

Dr. Daniel Levy joined Medinol in 2000 and he is responsible for all aspects of Quality at the company, including implementation of Good Manufacturing Practice (GMP) according to FDA's Quality System Regulation and ISO 13485, implementation of Good Distribution Practices and Quality Control testing and inspection.

Between 2005 and 2007, Dr. Levy was Quality Assurance Manager for Teva Pharmaceutical Industries. Prior to joining Medinol in 2000, he was Quality Assurance Manager for Perio Products. He also worked for International Diagnostic Laboratories for several years as the Head of the company’s Organic Chemistry and Biochemistry Group.

Dr. Levy holds a B.Sc. (with honors) in Chemistry from the University of London, Kings College and a Ph.D. in Organic Chemistry from the University of London, Westfield College. He also carried out Post Doctoral research in Chemical Physics at the Weizmann Institute of Science and has published numerous scientific articles.

Dr. Oleg Weizman - VP Innovative Technologies

With over 20 years of experience in the medical device industry, including R&D and engineering activities in the cardiovascular and urology fields, Dr. Weizman is leading the development of innovative technologies at Medinol. He joined the company in 1995 and previously he was Medinol’s R&D Manager.

Before joining Medinol, Dr. Weizman worked at Medispec, a medical device company. He also worked for Tel-Aviv University, where he participated in a joint project of ionosphere research with the US Army's CECOM.

Dr. Weizman holds a B.Sc. and M.Sc. in radio engineering from the Engineering Institute in Zaporozhye, Ukraine and a Ph.D. in Physics and Mathematics from the Institute of Terrestrial Magnetism, Ionosphere and Radio Wave Propagation of the Academy of Science of the USSR (IZMIRAN). He has published numerous articles in the areas of radio science and advanced space research.

Sachi Gerlitz - President Sales and Marketing

Sachi Gerlitz serves as the President, Sales and Marketing, of Medinol. He is also currently the Executive Chairman of Ness Technology Inc., a global IT services provider.

Previously, Mr. Gerlitz was President and CEO of Ness Technologies. Prior to joining Ness, Mr. Gerlitz was acting chairman of Mobixell Networks and Chairman of the Board of the Israel Mobile Association. From 2001 through 2006, Mr. Gerlitz was a partner at Apax Partners, a global private equity firm managing assets of over $25 billion, and was on the board of directors of a number of public and private companies, including Bezeq, Starhome BV, Crescendo Networks and Bitband Technologies. Prior to joining Apax Partners, Mr. Gerlitz held various positions at Comverse, Telrad Telecommunication Industries, Hadassah University Hospital, and in the Israeli Defense Forces.

Mr. Gerlitz has a B.Sc. in Electronic Engineering from Tel-Aviv University and is a graduate of the Business Administration Program for Industry Management from Bar-Ilan University.

Efi Haber Naor – VP HR and Infrastructure

Efi Haber Naor is leading Medinol's human resources organization, as well as the company's administration, logistics and procurement operations. She is also Director of the NIR School of the Heart, and heads the company’s community relations.

Prior to joining Medinol in 1999, Ms. Haber Naor worked at the Tel Aviv Municipality as Head of Community Services in the Northern District of Tel Aviv, where she was responsible for community projects in 13 Tel Aviv neighborhoods.

Ms. Haber Naor holds a BA in Community and Clinical Social Work (with honors) from The Hebrew University of Jerusalem, and has undergone professional training in mediation, conflict resolution and youth guidance.


Harvey J. Berger, M.D. – Executive Chairman Medinol USA

Harvey J. Berger, M.D. joined Medinol as Executive Chairman of Medinol USA in January 2017. At Medinol  Dr. Berger is focused on worldwide business development and global strategy, new business and technology initiatives and expanding operational efficiencies worldwide. He is working with Medinol’s core business of interventional cardiovascular devices, as well as its new businesses of developing sub-millimeter implantable sensors, unique percutaneous aortic valves and other complimentary medical products. 

Dr. Berger brings over 35 years of experience in the medical and biotechnology fields. Prior to joining Medinol,  he was the Chairman and Chief Executive Officer of ARIAD Pharmaceuticals, Inc. since founding the company over 25 years earlier, in which time the company developed into one of the leading global commercial oncology companies. It was acquired by Takeda Pharmaceuticals, Ltd. In 2017 and incorporated into Takeda Oncology. 

Dr. Berger was a Professor at Yale, Emory and University of Pennsylvania medical schools. He received his M.D. from Yale School of Medicine and did further medical and post-graduate training at Massachusetts General Hospital and Yale-New Haven Hospital. He was the award winner of the Ernst & Young Entrepreneur of the Year Award in New England and the Gold Stevie Award as Executive of the Year

Matt W. Donnelly – General Manager Medinol USA

Matt W. Donnelly joined Medinol in January 2014, assuming leadership of Medinol USA. He focuses on the commercial introduction of all Medinol product portfolios into the US market and is responsible for management of Medinol’s US headquarters in Parsippany, NJ including sales, marketing and operations. 

Prior to Medinol, Mr. Donnelly was Vice President US Sales and Marketing for Covidien Patient Monitoring, where he directed US sales and marketing teams, and led the development of marketing and sales strategies for the $500 million patient monitoring business. Before this, he was Vice President US Sales and Marketing for Biomet’s Spine and Bone Healing Divisions. In this role, he directed US sales and marketing teams and led the development of marketing and sales strategies for the $700 million division, including a hybrid sales organization of both direct and indirect sales representatives. Previously, he held senior sales and marketing Roles at Cordis, a division of Johnson and Johnson.

Mr. Donnelly holds a B.Sc. in Accounting from Christian Brother University.

Dafna Perlovitch - VP Finance

Dafna Perlovitch manages Medinol’s finance department, which runs the Company's financial reporting, domestic and global taxation, legal issues, comptrollership, budget and control. 

Prior to joining Medinol in 2005, Ms. Perlovitch was a Manager at Ernst & Young, responsible for managing audits for multiple large public and private companies and startups, handling due diligence for pre-acquisition of companies, supporting audited companies and being focal point for accounting issues, tax consulting and legal aspects of audits.

Ms. Perlovitch holds a BA in Accounting and Economics and an MBA, both from Tel Aviv University.

Dov Amar – VP Global Manufacturing Operations

Dov Amar joined Medinol in 2016 and leads the global manufacturing operations of the company.

Prior to joining Medinol, Mr. Amar held different positions in the metal and pharmaceutical industries. In his most recent position, Mr. Amar worked at Teva Pharmaceutical Industries. In his last position he assumed the role of Vice President TAPI (Teva API) global supply chain. Previously Mr. Amar held different positions in Teva's European Operations and Global Supply Chain organizations. Prior to working for Teva, Mr. Amar was the Vice President Operations at Carmel Forge, a subsidiary of Pratt & Whitney.  

Mr. Amar holds a B.Sc. in Industrial Engineering and Management from the Technion - Israel Institute of Technology and an MBA in Finance and Accounting from the Tel Aviv University.

© 2014 Medinol Ltd · MKW1004-0